The Leva® Anterior Expandable Spacer System is indicated for intervertebral body fission procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. Degenerative disc disease is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may have up to Grade I spondylolisthesis at the involved level(s). The Leva® Anterior Expandable Spacer System is to be used with autogenous bone graft and with supplemental fixation. Patients should have at least six (6) months of non-operative treatment with an intervertebral body fusion device.

Device Description

The Leva® Anterior Expandable Spacer is an expandable lumbar intervertebral body fusion device manufactured from unalloyed commercially pure titanium per ASTM F67. The Leva® Anterior Expandable Inserter, a reusable surgical instrument, expands the spacer (which is provided in a collapsed form) in situ to a predefined height. To accommodate the anatomical needs of a variety of patients, the spacer is available in a range of sizes. The superior and inferior surfaces of the spacer are convex with a lordotic angle to conform to the vertebral endplates, and ridges on both surfaces help resist expulsion. The spacer is designed to accommodate autogenous bone graft material.

AI/ML Overview

I am sorry, but the provided text describes a 510(k) premarket notification for a medical device (Leva® Anterior Expandable Spacer System), which is an intervertebral body fusion device. This documentation focuses on demonstrating substantial equivalence to predicate devices based on mechanical testing and material properties, rather than the performance of an AI or diagnostic device that would involve an AI algorithm.

Therefore, the document does not contain the information requested regarding acceptance criteria related to AI device performance, sample sizes for test/training sets, expert adjudication methods, MRMC studies, standalone algorithm performance, or ground truth establishment for such studies.

The acceptance criteria in this document relate to the physical and mechanical properties of the implant, such as:

Static and dynamic axial compression (per ASTM F2077)
Static and dynamic compression shear (per ASTM F2077)
Subsidence (per ASTM F2267)
Cadaveric validation

Since the input doesn't provide data for an AI-related medical device study, I cannot generate the requested table and information.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird with three wing-like shapes, representing the department's mission to protect the health of all Americans. The logo is surrounded by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

Spine Wave, Inc. Amy Noccioli Regulatory Affairs Specialist 3 Enterprise Drive, Suite 210 Shelton, Connecticut 06484

Re: K163246

Trade/Device Name: Leva® Anterior Expandable Spacer System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: MAX Dated: March 2, 2017 Received: March 3, 2017

Dear Ms. Noccioli:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely,

Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

Device Name

Leva® Anterior Expandable Spacer System

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and comblete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, fo:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the words "Spine Wave" in a bold, sans-serif font. The words are arranged horizontally, with "Spine" on the left and "Wave" on the right. A blue wave design is located under the text. The wave starts below the "N" in "Spine" and extends to the right, under the "W" in "Wave".

510(k) Summary Leva® Anterior Expandable Spacer System

1. Submitter Information

Submitter:	Spine Wave, Inc.
Address:	Three Enterprise DriveSuite 210Shelton, CT 06484
Telephone:	203-712-1842
Telefax:	203-944-9493
Contact:	Amy Noccioli
Date Prepared:	November 16, 2016

2. Device Information

Trade Name:	Leva® Anterior Expandable Spacer System
Common Name:	Intervertebral Body Fusion Device
Classification:	Class II (special controls) per 21 CFR 888.3080
Classification Name:	Intervertebral Fusion Device with Bone Graft, Lumbar
Product Code:	MAX

3. Purpose of Submission

The purpose of this submission is to gain clearance for a new intervertebral body fusion device.

4. Predicate Device Information

The Leva® Anterior Expandable Spacer System described in this submission is substantially equivalent to the following predicates:

Primary Predicate Device	Manufacturer	510(k) No.
Leva® Spacer System	Spine Wave, Inc.	K141980

Reference Predicate Devices	Manufacturer	510(k) No.
MAGNIFYTM Spacer	Globus Medical, Inc.	K142498
PATRIOT® Spacer	Globus Medical, Inc.	K072970

{4}------------------------------------------------

5. Device Description

6. Indications for Use

The Leva® Anterior Expandable Spacer System is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. Degenerative disc disease is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). The Leva® Anterior Expandable Spacer System is to be used with autogenous bone graft and with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral body fusion device.

7. Comparison of Technological Characteristics

The Leva® Anterior Expandable Spacer System has technological characteristics similar to the predicate devices, including intended use, performance, design, material composition, and range of sizes.

8. Performance Data

Spine Wave performed the following testing to demonstrate that the Leva® Anterior Expandable Spacer System is substantially equivalent to its predicate:

o Static and dynamic axial compression (per ASTM F2077)
Static and dynamic compression shear (per ASTM F2077)
Subsidence (per ASTM F2267)
Cadaveric validation o

9. Conclusion

The indications for use, technological characteristics, performance testing, and comparison to the predicates show that the Leva® Anterior Expandable Spacer System is substantially equivalent to the predicate devices identified in this submission and does not present any new issues of safety or effectiveness.

Regulation Number and Section

§ 888.3080 Intervertebral body fusion device.

(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.